CoChat
Sign Up
Cited by 156Economic and Financial Impacts of CancerHealthcare Policy and ManagementGlobal Cancer Incidence and Screening

Cancer treatment cost in the United States: Has the burden shifted over time?

Tangka, Florence K., Trogdon, Justin G., Richardson, Lisa C., Howard, David, Sabatino, Susan A., Finkelstein, Eric A.·2010·Cancer
DOI 10.1002/cncr.25150
Open this paper in CoChat — free account

Abstract

BACKGROUND: There has not been a comprehensive analysis of how aggregate cancer costs have changed over time. The authors present 1) updated estimates of the prevalence and total cost of cancer for select payers and how these have changed over the past 2 decades; and 2) for each payer, the distribution of payments by type of service over time to assess whether there have been shifts in cancer treatment settings. METHODS: Pooled data from the 2001 through 2005 Medical Expenditure Panel Survey and the 1987 National Medical Care Expenditure Survey were used for the analysis. The authors used an econometric approach to estimate cancer‐attributable medical expenditures by payer and type of service. RESULTS: In 1987, the total medical cost of cancer (in 2007 US dollars) was $24.7 billion. Private payers financed the largest share of the total (42%), followed by Medicare (33%), out of pocket (17%), other public (7%), and Medicaid (1%). Between 1987 and the 2001 to 2005 period, the total medical cost of cancer increased to $48.1 billion. In 2001 to 2005, the shares of cancer costs were: private insurance (50%), Medicare (34%), out of pocket (8%), other public (5%), and Medicaid (3%). The share of total cancer costs that resulted from inpatient admissions fell from 64.4% in 1987 to 27.5% in 2001 to 2005. CONCLUSIONS: The authors identified 3 trends in the total costs of cancer: 1) the medical costs of cancer have nearly doubled; 2) cancer costs have shifted away from the inpatient setting; and 3) the share of these costs paid for by private insurance and Medicaid have increased. Cancer 2010. Published 2010 by American Cancer Society.

Integrity signals

Registry

Crossref · 10.1002/cncr.25150

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • $74.9 billion of health care costs in 2013 were for uncompensated care received by those without insurance.

    “It was estimated that $74.9 billion of the health care costs in 2013 were for uncompensated care received by those without insurance.30”

    From US Health Care Spending by Payer and Health Condition, 1996-2016 (2020) · cites this paper as [30]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Tangka, F. K., Trogdon, J. G., Richardson, L. C., Howard, D., Sabatino, S. A., & Finkelstein, E. A.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • RTI International (US)
  • Emory University (US)
  • National University of Singapore (SG)
Corresponding author
Tangka, Florence K.
ORCID
Venue
Cancer
Publisher
Wiley
Published
2010-05-10
Volume
116
Issue
14
Pages
3477-3484
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
DOI
10.1002/cncr.25150
OpenAlex
W1590770963
Cited by
156
References
22
Citations by year
2025: 2 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 11 · 2020: 15 · 2019: 10 · 2018: 9 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 11 · 2013: 16 · 2012: 14
FWCI
39.24
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Cancer (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Keywords
cancer treatment costs, health care costs, cost trends, Medicare, Medicaid, private insurance, out-of-pocket costs, hospitalization, outpatient care, cancer prevalence, United States
MeSH terms
Financing, Government, Financing, Personal, Medicare, Humans, Inpatients, Insurance, Health, Medicaid, Neoplasms, Outpatients, United States, Prevalence, Drug Costs, Health Care Costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review